HCAR2 antibody (Middle Region)

Catalog No. ABIN952597

Product Details anti-HCAR2 Antibody

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Binding Specificity: AA 207-236, Middle Region

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HCAR2 antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificity: This antibody recognizes Human GRP109A (Center). Other species not tested.

Purification: Protein A column, followed by peptide affinity purification

Immunogen: KLH conjugated synthetic peptide between 207-236 amino acids from the Central region of human GPR109A Genename: NIACR1

Isotype: Ig Fraction

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for HCAR2

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Alternative Name: GPR109A (HCAR2 Products)

Synonyms: GPR109A antibody, HCA2 antibody, HM74a antibody, HM74b antibody, NIACR1 antibody, PUMAG antibody, Puma-g antibody, Gpr109a antibody, Gpr109b antibody, HM74 antibody, Hcar2 antibody, PUMA-G antibody, Pumag antibody, mHM74b antibody, HCAR2 antibody, HCAR3 antibody, hydroxycarboxylic acid receptor 2 antibody, HCAR2 antibody, Hcar2 antibody, LOC527744 antibody

Background: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamideSynonyms: G-protein coupled receptor 109A, G-protein coupled receptor HM74A, HM74A, NIACR1, Niacin receptor 1, Nicotinic acid receptor, PUMA-G, Pumag

Molecular Weight: 41850 Da

Gene ID: 338442

NCBI Accession: NP_808219